Bionano Genomics Inc - BNGO STOCK NEWS

Bionano Genomics (BNGO) reported Q4 2024 financial results with total revenue of $8.2 million, down 24% from Q4 2023. Full-year 2024 revenue was $30.8 million, a 15% decrease from 2023. Despite challenges, the company achieved a 42% GAAP gross margin in Q4 2024, up from 23% in Q4 2023.

Key operational highlights include:

• Installed base grew 14% to 371 OGM systems
• Flowcell sales increased 15% to 30,307 units in 2024
• Published 336 OGM publications, up 19% from 2023

The company provided 2025 guidance of $29.0-$32.0 million in revenue and plans to install 15-20 new OGM systems. Cost reduction efforts have decreased annualized operating expenses by approximately $100 million. Cash runway extends into Q1 2026, supported by recent financing activities including a $10 million Registered Direct Offering in January 2025.

Bionano Genomics (BNGO) and Greenwood Genetic Center published groundbreaking research in Genome Research using optical genome mapping (OGM) to study neural tube defects (NTDs). The study analyzed 104 NTD cases, revealing significant findings:

The research detected:

• Pathogenic structural variants in 8% of cases (8/104)
• Variants affecting known NTD pathway genes in 13% of cases (14/104)
• Variants affecting NTD-associated genes from mouse models in 9% of cases (9/104)

The study identified four novel candidate genes (RMND5A, HNRNPC, FOXD4, and RBBP4) potentially linked to NTDs and expanded clinical implications for AMER1 and TGIF1. With NTDs affecting approximately 300,000 births annually worldwide, this research provides new insights into genetic factors in 30% of combined cases, potentially improving future patient management and therapeutic interventions.

Bionano Genomics (BNGO) has announced its participation in the American College of Medical Genetics and Genomics (ACMG) Annual Meeting 2025, scheduled for March 18-22 in Los Angeles. The company will present extensive research on Optical Genome Mapping (OGM) applications through various sessions and posters.

A featured CME session titled 'Evolution of Cytogenomic Technology' will showcase OGM's real-world applications, featuring presentations from leading experts including:

• Dr. Adam Smith (Labcorp) on OGM's role in hematological malignancy research
• Dr. Laila El-Khattabi (Sorbonne) presenting CHROMAPS project results
• Dr. Nikhil Sahajpal (Greenwood Genetic Center) discussing findings from clinical research cohorts
• Dr. Rashmi Kanagal-Shamanna (MD Anderson) on integrated OGM approaches

The company notes it will operate with a reduced footprint to control expenses while maintaining a strong scientific presence.

Bionano Genomics (BNGO) has scheduled its fourth quarter and full year 2024 financial results conference call and webcast for March 31, 2025, at 4:30 p.m. Eastern Time. During the call, the company will present its financial performance and discuss recent corporate developments.

The event will be accessible to participants through a live webcast on the Investors section of Bionano's website. A replay of the presentation will remain available on the company's investor relations website at ir.bionano.com for a minimum of 30 days following the event.

Bionano Genomics (BNGO) has announced groundbreaking research published in the American Journal of Hematology showcasing the first-ever use of optical genome mapping (OGM) to detect chromoanagenesis (CAG) in acute myeloid leukemia (AML).

The study, led by Dr. Guilin Tang at MD Anderson Cancer Center, analyzed 410 AML cases and revealed that CAG was present in 16% of cases, with notably higher occurrence in high-risk cytogenetic profiles. Key findings showed that patients with CAG had:

• Only 5 months median survival vs 14 months without CAG
• Strong correlation with complex karyotypes (92%)
• High association with TP53 mutations (92%)
• Significantly lower response to combination therapy

The research suggests OGM may be more sensitive than traditional cytogenetic methods in identifying aggressive forms of AML, potentially enabling earlier appropriate therapy intervention for patients.

Bionano Genomics (BNGO) has announced a 1-for-60 reverse stock split of its common stock, effective at 5 p.m. ET on January 24, 2025. Trading on a split-adjusted basis will begin on January 27, 2025. The split was approved by stockholders at a special meeting on January 15, 2025, where the Board was authorized to implement a ratio between 1-for-25 and 1-for-75.

The reverse split will automatically convert every 60 existing shares into one new share. The stock will continue trading under the symbol 'BNGO' on Nasdaq Capital Market but with a new CUSIP number (09075F404). The split proportionally affects all outstanding convertible debentures, stock options, restricted stock units, and warrants, adjusting their conversion and exercise prices accordingly. No fractional shares will be issued; instead, affected stockholders will receive cash payments.

Bionano Genomics (BNGO) announced a breakthrough case study from Shenzhen Maternity and Child Healthcare Hospital, demonstrating the successful application of their optical genome mapping (OGM) technology in preimplantation genetic testing. The study showcases how OGM identified complex chromosomal rearrangements (CCRs) that were missed by traditional cytogenetic methods in a male partner of a couple experiencing recurrent pregnancy loss (RPL).

Using OGM as part of an in-vitro fertilization (IVF) and preimplantation genetic testing protocol, doctors were able to select the most viable embryo, resulting in a successful pregnancy and the birth of a healthy baby. This achievement is particularly significant as RPL affects millions worldwide, and infertility impacts 1 in 6 couples.

Bionano Genomics (Nasdaq: BNGO) reported preliminary unaudited financial results for Q4 and FY 2024. Q4 2024 revenue is expected to be between $7.9 and $8.1 million, a decrease of approximately 25% compared to Q4 2023, due to discontinuation of clinical service products. However, this represents a 30-33% increase from Q3 2024. The installed base of optical genome mapping (OGM) systems reached 371, a 14% increase over 2023. The number of nanochannel array flowcells sold in Q4 2024 is expected to be 8,058, a 1% increase over Q4 2023. Full-year 2024 revenue is projected to be between $30.5 and $30.7 million, a decrease of approximately 15% from 2023.

Bionano highlighted significant milestones, including the full commercial release of the high-throughput Stratys™ system and advancements in their VIA™ software. Cash, cash equivalents, and available-for-sale securities as of December 31, 2024, were approximately $20.9 million, with $11.4 million subject to restrictions. The company raised net proceeds of $3.6 million from ATM sales in Q4 2024 and $1.9 million in early 2025, along with $10.0 million from a registered direct offering. Bionano also modified its senior secured convertible debentures to defer payments and reduce monthly obligations.

Bionano Genomics announced a publication from Johns Hopkins University demonstrating that optical genome mapping (OGM) can identify structural variants in acute promyelocytic leukemia (APL) that conventional cytogenetic techniques often miss.

The case study showed that OGM detected a PML::RARA fusion variant, which was not identified by karyotyping and non-informative by FISH. This fusion is significant as APL, an aggressive subtype of acute myelogenous leukemia (AML), responds well to treatments like all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). However, about 13% of APL cases are not properly identified by conventional methods, potentially hindering effective treatment.

OGM's ability to detect these variants aligns with previous findings, suggesting it could be a more reliable alternative for guiding therapy selection and patient management. Bionano's CEO, Erik Holmlin, emphasized that OGM's higher resolution and streamlined workflow make it a promising tool for improving treatment decisions in blood cancer cases.